Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST
Covered in this story
What has happened since
- Parker Hannifin is down 17.0% since this was published, 74 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Parker Hannifin
- Stifel: $962 → $1.07k by Oct 2027 · Hold via Investing.com
- TD Cowen: $954 → $950 by Oct 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Parker Hannifin →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.